Clinical Trial Update: A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daclizumab for bone marrow failure (aplastic anemia and related conditions) was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Diamond-blackfan Anemia
• Pure Red Cell Aplasia

Drugs mentioned

• Daclizumab (daclizumab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Aplastic Anemia, Pure Red Cell Aplasia | Phase 2 | Status: TERMINATED | Results posted: 2015-05-14